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ABSTRACT
RhoE is a small GTPase involved in the regulation of actin cytoskeleton dynamics, 
cell cycle and apoptosis. The role of RhoE in cancer is currently controversial, with 
reports of both oncogenic and tumor-suppressive functions for RhoE. Using RhoE-
deficient mice, we show here that the absence of RhoE blunts contact-inhibition 
of growth by inhibiting p27Kip1 nuclear translocation and cooperates in oncogenic 
transformation of mouse primary fibroblasts. Heterozygous RhoE+/gt mice are more 
susceptible to chemically induced skin tumors and RhoE knock-down results in 
increased metastatic potential of cancer cells. These results indicate that RhoE plays 
a role in suppressing tumor initiation and progression.
INTRODUCTION
RhoE/Rnd3 is an atypical member of the Rho family 
of proteins that negatively regulates the RhoA-ROCK 
pathway [1-5]. RhoE overexpression inhibits cellular 
proliferation, blocking the cell cycle in G1 [6-9]. Besides, 
RhoE is regulated along the cell cycle, accumulating in 
G1 and being rapidly degraded at the G1/S transition in a 
proteasome-dependent manner, and it also accumulates in 
primary fibroblasts reaching confluency [9]. RhoE is also 
induced by genotoxic stress in a p53 dependent fashion, 
acting as a pro-survival factor [10, 11]. 
The role of RhoE in cancer is not clear at present. 
Some reports suggest a possible tumor suppressor 
role for RhoE in human cancer and metastasis [7, 12-
19]. However, additional evidence suggests a positive 
correlation between RhoE expression and malignancy 
[20-26]. 
By using mice in which RhoE expression has been 
ablated by a gene-trap cassette [27], we show here that this 
protein is dispensable for normal cellular proliferation, 
but its absence: a) causes lack of contact inhibition; b) 
cooperates with oncogenes in cellular transformation; c) 
increases susceptibility to chemical carcinogens in vivo; 
and d) increases the metastatic potential of cancer cells. 
These results demonstrate that RhoE contributes to tumor 
suppression.
RESULTS
RhoE is necessary for contact inhibition
In order to test the role of RhoE in the control of 
cell proliferation, we analyzed the growth of primary 
Mouse Embryo Fibroblasts (MEFs) from RhoE deficient 
mice (RhoEgt/gt) as well as from wild-type (RhoE+/+) 
and hemizygous (RhoE+/gt) animals. MEFs of the three 
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genotypes showed similar growth rates (Figure 1A, 
left) and undistinguishable cell cycle profiles either in 
asynchronous growth, during serum starvation or upon 
serum re-addition (Figure 1A, right panels). From these 
results, the absence of RhoE expression does not have a 
clear effect on normal cell proliferation.
Figure 1: RhoE is a mediator of contact inhibition. A. Lack of RhoE expression does not affect cell proliferation. Left: Primary 
MEFs were grown in DMEM-10% FBS and fixed at the indicated time points. Cell density was measured by crystal violet staining. Data 
(referred to time 0) from three independent experiments are shown as Mean+SEM. A.U.: arbitrary units. Right: Cell cycle profile of primary 
MEFs growing in 10% FBS (Asynchronous), serum-starved for 48 h (No serum) or re-stimulated for 16 h after serum-starvation (Re-
stimulated) was analyzed by flow cytometry after DNA staining with Propidium Iodide. B. RhoE deficient cells are not contact inhibited. 
RhoE+/+, RhoE+/gt and RhoEgt/gt primary MEFs were kept in culture for 15 days and cell density was measured by crystal violet staining. 
Pictures show examples of the plates after staining. The graph shows the Mean+SEM of three independent experiments (*p < 0.05 and 
***p < 0.001 in a Student’s t test). A.U.: arbitrary units. C. p27Kip1 accumulates normally in high density cultures in the absence of RhoE. 
Primary MEFs as in B were kept in culture for 8 days with medium-change every 48 h. At the indicated time-points, the expression of RhoE 
and p27Kip1 was analyzed by Western blotting. Actin was used as a loading control. D. p21Cip1 expression does not change in the absence of 
RhoE expression. RhoE+/+ and RhoEgt/gt primary MEFs were kept in culture for 8 days and the expression of p21Cip1 and RhoE was analyzed 
as in C. 
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RhoE accumulates in cells growing at high density 
[9], suggesting that it might be involved in the regulation 
of contact inhibition. To test this hypothesis, we measured 
the cell density reached by primary fibroblasts from 
RhoEgt/gt and RhoE+/gt mouse embryos kept in culture for 
15 days and compared it to that of RhoE+/+ cells. Figure 
1B shows that RhoEgt/gt MEFs reached densities four times 
higher than wild type cells. Interestingly, RhoE+/gt MEFs 
displayed an intermediate behavior, suggesting a possible 
gene dosage effect.
The cell cycle inhibitor p27Kip1 mediates contact 
inhibition in response to cadherins [28-30]. Also, RhoE 
accumulates in high density cultures and follows the same 
expression pattern as p27Kip1 [9]. Therefore, we reasoned 
Figure 2: RhoE is necessary for nuclear localization of p27Kip1 in high density cultures.  A. RhoE+/+ and RhoEgt/gt primary 
MEFs were kept in culture for 8 days and at the indicated time points nuclear-cytoplasm fractionation was performed as indicated in the 
Methods section. The expression of p27Kip1 in both fractions was analyzed by Western blotting. Lamin A and β-tubulin were used as controls 
for purity of the nuclear and cytoplasmic fractions, respectively. The bottom panel shows a longer exposure of the p27Kip1 blot. B. The 
expression of p27Kip1 in the nuclear and cytoplasmic fractions of MCF7 and shRhoE-MCF7 cells in high density cultures was analyzed 
as in A. C. RhoE silencing in MCF7 cells was analyzed by Western blotting in extracts from control or shRhoE-transduced MCF7 cells.
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that there could be a functional link between these two 
proteins. To test whether RhoE could affect the expression 
of p27Kip1, we analyzed the levels of this protein at 
different time points along the experiment (Figure 1C). 
In wild type MEFs, both p27Kip1 and RhoE accumulated 
as they reached saturation. p27Kip1 also accumulated in 
RhoE+/gt and in RhoEgt/gt MEFs to the same extent as in 
wild type cells, indicating that, in the absence of RhoE 
expression, primary MEFs are able to keep proliferating 
to high density even in the presence of high p27Kip1 levels 
(Figure 1C). We also analyzed the expression along the 
experiment of other cell cycle regulators, such as the 
CDK inhibitor p21Cip1 or cyclins D and E, but there was no 
difference between wild type and RhoEgt/gt MEFs (Figure 
1D and data not shown).
RhoE is required for correct localization of p27Kip1 
to the nucleus in high density cultures
Subcellular localization is crucial for p27Kip1 
function. Although p27Kip1 works as an inhibitor of cell 
cycle progression when located in the nucleus, it shows 
oncogenic properties as a cytoplasmic protein [31, 32]. 
We therefore analyzed the localization of p27Kip1 in MEFs 
reaching high densities. As shown in Figure 2A, p27Kip1 
entered the nucleus in RhoE+/+ cells after 4 days in culture 
(left panel). In contrast, p27Kip1 could not be detected in 
the nuclear fraction of cells lacking RhoE expression and 
remained in the cytoplasmic fraction throughout the length 
of the experiment (right panel).
We wanted to extend this finding to other cell 
types. For that purpose we used the MCF7 human breast 
adenocarcinoma cell line, in which we knocked-down 
RhoE expression by using shRNA (Figure 2C). After 4 
days in culture, p27Kip1 accumulated in MCF7 cells and 
was also abundant in the nuclear fraction (Figure 2B, 
left panel). In contrast, p27Kip1 nuclear accumulation was 
dramatically blunted when RhoE expression was knocked-
down and p27Kip1 could only be detected in the nuclear 
fraction after 8 days in culture and in longer exposed films 
(Figure 2B, right panel). 
Lack of RhoE expression facilitates spontaneous 
immortalization and oncogenic transformation
The ability of RhoEgt/gt primary MEFs to reach 
higher densities in culture could reflect suppression of 
senescence. To test this hypothesis, we performed a 3T3 
serial passage protocol [33] to follow entry into, and exit 
from, senescence. Our results revealed no significant 
differences in the passage number at which cells entered 
senescence (RhoE+/+, 6.0±1.3; RhoE+/gt, 5.1±0.6; RhoEgt/
gt, 5.6±2.7). However, while RhoE+/+ cells immortalized 
at passage number 16.0±1.5, RhoE+/gt and RhoEgt/gt MEFs 
exited senescence at an earlier passage (9.8±0.9 and 
10.3±0.8, respectively; p < 0.05 vs RhoE+/+ in a Student´s 
t test).
We next asked whether the absence of RhoE 
expression would also increase the transforming ability of 
oncogenes in a colony formation assay. Oncogenic RasV12 
alone was unable to induce colony formation in wild type 
or RhoEgt/gt primary MEFs, while the combination E1A/
RasV12 resulted in the apparition of colonies. However, 
RhoEgt/gt MEFs showed a threefold increase in the number 
of colonies compared to RhoE+/+, indicating that the 
absence of RhoE cooperates with E1A/RasV12 in oncogenic 
transformation (Figure 3A). Finally, we tested the ability 
of the transformed cells to form tumors in nude mice. 
Tumors derived from E1A/RasV12-transformed RhoEgt/gt 
 MEFs grew more rapidly than those expressing RhoE 
(Figure 3B). This indicates that the absence of RhoE 
expression facilitates transformation and tumorigenesis.
Absence of RhoE expression increases 
susceptibility to chemically induced skin tumors
To study whether RhoE could also behave as a tumor 
suppressor in vivo, we evaluated the susceptibility of RhoE 
hemizygous mice to chemically induced carcinogenesis, 
using a DMBA/TPA two-stage skin carcinogenesis 
protocol [34, 35]. We could not use RhoEgt/gt mice in 
this experiment because of their short lifespan [27]. 
Papillomas started to appear at the same time in RhoE+/gt 
 and in RhoE+/+ mice. However, the number of tumors 
per mice was significantly higher in the RhoE+/gt group 
than in wild type mice (Figure 4A). Moreover, tumors 
grew significantly faster in RhoE+/gt than in RhoE+/+ mice, 
with 50% of them being larger than 2 mm at week 12 of 
treatment in the RhoE+/gt mice and at week 17 in the wild 
types (Figure 4B). Finally, we analyzed the progression 
to carcinomas after stopping the TPA treatment, finding 
that the conversion rate was double in RhoE+/gt than in 
RhoE+/+ mice (Figure 4C). Therefore, a decrease in RhoE 
expression contributes to tumor progression.
Additionally, we analyzed the proliferative response 
in the skin after a single TPA dose administered topically. 
In this case, we used young animals (15 days old) and thus 
we were able to include also RhoEgt/gt mice. The number 
of proliferating cells, measured as PCNA positive nuclei, 
increased in the three groups 24 h after TPA treatment, 
compared to untreated controls (Figure 4D). However, this 
increase was significantly larger in RhoE+/gt and RhoEgt/gt 
mice than in RhoE+/+ controls. Interestingly, Western blot 
analysis of skin lysates showed that the expression of 
RhoE in the skin of wild type animals increased after a 
single dose of TPA (Figure 4E).
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Figure 3: RhoE deficiency cooperates with E1A and RasV12. A. Primary MEFs were infected with retroviruses containing empty 
pLPC (Vector), pLPC-RasV12 or pLPC-E1A/RasV12, selected for 3 days with Puromycin and kept in culture for 1 week (RasV12 or E1A/
RasV12) or 3 weeks (empty vector). Transformed colonies were stained with crystal violet and counted. Mean+SD of two independent 
experiments is plotted (bottom graph). B. RhoE+/+ and RhoEgt/gt MEFs previously infected with pLPC-E1A/RasV12 were subcutaneously 
injected into the left and right flanks of nude mice (4x105 cells in 100 µl of PBS per injection). Tumor volume was calculated every 4 days. 
Mean±SEM is plotted (left) and a representative example is shown (right). Differences between RhoE+/+ and RhoEgt/gt are significant in a 
2 way ANOVA (p < 0.0001).
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Figure 4: RhoE protects from DMBA/TPA-induced skin tumors in mice. A. Average number of tumors in RhoE+/+ and RhoE+/gt 
mice (n = 14 each) treated with DMBA/TPA. TPA treatment was discontinued after week 15. Differences between both genotypes were 
significant in a 2 way ANOVA (p < 0.0001). B. Percentage of mice having tumors bigger than 2 mm. p = 0.0145 in a Mantel-Cox test. C. 
After the DMBA/TPA treatment, mice were sacrificed and lesions classified as papilloma or squamous cell carcinoma (SCC). Representative 
images of papilloma (left) and SCC (right) from a RhoE+/gt mouse are shown. Percentage of carcinomas relative to the maximum number 
of papillomas is represented (right). In RhoE+/+ mice, 1 carcinoma was found from a maximum of 47 papillomas at week 15, whereas in the 
case of RhoE+/gt mice, 7 carcinomas from 151 papillomas were found. Thus, the conversion rate from papilloma to carcinoma was 2.1% for 
RhoE+/+ and 4.6% for RhoE+/gt mice, and is shown in the graph on the right. D. RhoE expression reduces the induction of proliferation by 
TPA. Mice of the three genotypes (RhoE+/+, RhoE+/gt and RhoEgt/gt, n = 3 of each one) were treated with a single dose of TPA (12.5 µg in 0.2 
ml acetone) for 24 h. Percentage of PCNA positive nuclei determined by immunohistochemistry is plotted (**p < 0.01 and ***p < 0.001 in 
a 2 way ANOVA followed by Bonferroni’s multiple comparisons test). E. TPA induces the expression of RhoE in skin. RhoE expression in 
skin samples from control and TPA-treated RhoE+/+ mice (as in A) was analyzed by Western blotting. Actin was used as a loading control.
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RhoE silencing increases the metastatic potential 
of MDA-MB-231 cells
Finally, we wanted to test whether RhoE could be 
involved in metastasis. By using shRNA, we were able 
to achieve efficient RhoE expression knock-down (up 
to 68%) in breast carcinoma MDA-MB-231-TGL cells, 
which contain a GFP-luciferase cassette (Figure 5A). To 
Figure 5: RhoE expression reduces metastatic potential of MDA-MB-231 cells. A. MDA-MB-231-TGL cells were transduced 
with control lentivirus (pLKO.1) or three different shRNA constructs to knock-down RhoE expression. Knock-down efficiency was 
analyzed by Western blotting. Numbers show the relative expression level of RhoE after quantification by densitometry. B. After injection 
of MDA-MB-231-TGL cells (control and RhoE knock-down, using two different shRNAs) in the tail vein of 6 nude mice (2 per construct), 
lung tumors were analyzed every week by in vivo bioluminescence imaging and normalized photon flux was plotted (left graph). The 
image on the right shows representative results of mice injected with control (pLKO.1) and shRhoE #3 MDA-MB-231-TGL cells. C. Lung 
colonization by MDA-MB-231 cells. At the end of the experiment, lungs were removed and inspected to confirm the presence of tumors 
resulting from the injection of control (pLKO.1, left) and RhoE knocked-down (shRhoE #3, right) MDA-MB-231-TGL cells. Hematoxylin 
and eosin staining (bottom images, 200x) revealed no differences between control- and shRhoE- induced metastases tumors.
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test their metastatic potential, control and RhoE knock-
down (shRhoE #3 and #5) MDA-MB-231-TGL cells were 
injected in the tail vein of nude mice and the appearance 
of metastases was followed by in vivo bioluminescence 
[36]. After 9 weeks, all the mice showed lung metastases, 
as expected, but mice injected with shRhoE cells showed 
significantly higher metastatic signals than vector-bearing 
controls (Figure 5B). After necropsy, visual inspection of 
the lungs confirmed the higher colonization by shRhoE 
cells compared to pLKO.1 control cells, although 
hematoxylin and eosin staining showed no obvious 
differences between control- and shRhoE- induced 
metastases (Figure 5C). From these experiments, we can 
conclude that a reduction in RhoE expression increases the 
metastatic potential of tumor cells in vivo, suggesting that 
RhoE is a suppressor of metastasis.
DISCUSSION
In this work we have addressed the possible 
implication of RhoE in tumorigenesis. For this purpose, 
we have used primary MEFs and mice lacking RhoE 
expression (RhoEgt/gt), as well as shRNA to knock-down 
RhoE expression in cancer cells. Our results show that 
lack of RhoE expression suppresses contact inhibition, 
facilitates spontaneous immortalization and oncogenic 
transformation and increases tumorigenesis and metastatic 
potential of tumor cells. 
The role of RhoE in cancer is currently unclear. 
Previous studies with different tumor types have 
suggested a positive correlation of RhoE expression with 
tumor malignancy [20-26] but also a tumor suppressive 
function for RhoE [7, 12-19]. Our in vitro and in vivo 
results clearly support that RhoE contributes to tumor 
suppression. The contrasting evidence regarding the role 
of RhoE in tumorigenesis could be due to differences in 
cell or tumor types, alterations in regulators or mediators 
of RhoE function or experimental details. Regarding cell 
type specificity, our data with primary fibroblasts and 
epidermal carcinogenesis is in agreement with evidence of 
a tumor suppressor role of RhoE in mesenchymal tumors 
[12] or squamous cell carcinoma [15]. Further examples 
of cell-type specificity are the reports of tumor suppressive 
function in liver tumors [13, 14] or oncogenic in lung 
tumors [20, 21]. However for other tumor types (gastric, 
prostate and colorectal carcinoma) both functions have 
been reported [7, 16, 17, 22-25]. Our results suggest that 
RhoE tumor suppressive function is mediated at least in 
part by a mechanism involving nuclear translocation of 
p27Kip1. Interestingly, p27Kip1 localization can be a marker 
for prognosis and response to treatment in several different 
types of cancer [38]. It would be interesting to correlate 
the different roles of RhoE in tumors with p27Kip1 levels 
and localization. 
Although the expression of RhoE is dispensable 
for cell cycle progression in low density conditions, it is 
necessary for the correct control of cellular proliferation in 
high density cultures of primary MEFs. Contact inhibition 
is a mechanism to inhibit cell proliferation that is lost 
during tumorigenesis [39]. It controls cell number even 
in the presence of mitogens. Contact inhibited cells do not 
enter senescence and are viable after replating [40]. The 
best characterized event leading to contact inhibition is 
the induction of p27Kip1 expression, mediated by cadherins 
[28-30]. In fact, it has been shown that p27Kip1 induction, 
leading to contact inhibition, could be suppressing 
geroconversion which, in turn, is induced by mTOR 
mediated upregulation of the cell cycle inhibitor p21Cip1 
[40]. Our results show that, p27Kip1 and RhoE are both 
accumulated in primary MEFs and breast carcinoma cells 
when they are contact-inhibited. These two proteins show 
the same expression kinetics along the cell cycle and are 
degraded through, at least, a similar mechanism involving 
the E3 Ubiquitin ligase Skp2 and the proteasome [9, 
41, 42]. Besides, the expression of both proteins is 
downregulated by miR-200b in colorectal cancer [17]. 
All these data and our results presented here suggest that 
p27Kip1 and RhoE may have related functions in controlling 
excessive proliferation.
Primary fibroblasts lacking RhoE expression are 
able to reach higher densities in culture than wild type 
cells, despite the normal induction of p27Kip1. However, 
for p27Kip1 to behave as a cell cycle inhibitor, it needs 
to be translocated to the cell nucleus. Nuclear import of 
p27Kip1 depends on several phosphorylation events and 
interaction with different proteins [43]. In primary MEFs 
and MCF7 cells lacking RhoE expression, p27Kip1 is not 
properly translocated to the nucleus. This could explain 
why these cells do not seem to be contact inhibited. The 
mechanism by which RhoE contributes to the regulation 
of p27Kip1 localization remains to be determined. It has 
been recently shown that RhoE is necessary for proper 
nuclear translocation of the Notch intracellular domain 
(NICD) by forming a complex with importins in squamous 
cell carcinomas [15]. It is feasible that RhoE could use 
a similar mechanism involving formation of importin-
p27Kip1 complexes to mediate p27Kip1 nuclear translocation.
In our study, we focused on two cellular and animal 
models to study the impact of RhoE in tumorigenesis. 
First, we show here that lack of RhoE expression 
increases the susceptibility of primary MEFs to oncogenic 
transformation by E1A/RasV12, in agreement with a 
previous work reporting that RhoE overexpression inhibits 
Ras transformation of NIH3T3 fibroblasts [6]. Second, our 
results show the importance of RhoE in vivo in controlling 
chemically induced proliferation, tumor formation and 
progression in the skin. It has been reported that RhoE 
expression is upregulated in the skin by genotoxic stress 
[10, 11] and it can control proliferation and differentiation 
of keratinocytes in vitro by regulating Notch1 signaling 
[15, 44]. We now show that TPA treatment results in 
the accumulation of RhoE in the skin. This observation 
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could be related to the reported phosphorylation of 
RhoE by PKC that could lead to stabilization of RhoE 
[45, 46]. The lack of RhoE expression also results in 
increased proliferation in the skin after TPA treatment, 
indicating that RhoE contributes to controlling excessive 
proliferation in this context. Furthermore, we show that 
RhoE deficiency promotes both initiation (incidence of 
papillomas) and progression (conversion to carcinomas) 
in a skin chemical carcinogenesis model. In addition, 
decreased RhoE expression also increases the metastatic 
potential of tumor cells in vivo, suggesting that RhoE is 
a suppressor of metastasis, at least of the last stages of 
the process related with infiltration and colonization [37]. 
ROCK activity is necessary for the ameboid movement 
that allows migration and invasion of cancer cells [19, 
47]. As RhoE inhibits ROCK activity, this could be a 
mechanism by which it may contribute to negatively 
regulate tumor metastasis.
In summary, our results indicate that RhoE is 
involved in the control of contact inhibition by regulating 
p27Kip1 localization, negatively regulates excessive 
proliferation induced by oncogenes and carcinogens and 
limits metastatic potential of cancer cells, and therefore 
suggest an important role of RhoE in tumor suppression.
MATERIALS AND METHODS
Animal procedures
All animal procedures were approved by the 
local ethics committee (Ethics Committee for Animal 
Welfare of the Universidad CEU Cardenal Herrera, 
ID#CEBA-09/006), met the local guidelines (Spanish law 
53/2013), European regulations (EU directive 86/609) 
and Standards for Use of Laboratory Animals A5388-01 
(NIH). All efforts were made to minimize the number of 
animals used and their suffering. Mice were sacrificed by 
cervical dislocation.
Mice deficient for RhoE expression (RhoEgt/gt) were 
generated by insertion of a gene-trap cassette in intron 2 of 
the gene [48]. The resulting phenotype has been described 
previously [27].
Hsd:Athymic Nude-Foxn1nu immunocompromised 
mice were obtained from Harlan Laboratories 
(Indianapolis, IN, USA).
Cell culture and proliferation analysis
All cells were maintained in high glucose 
Dulbecco’s modified Eagle’s (DMEM) supplemented with 
10% FBS. 
Primary Mouse Embryonic Fibroblasts (MEFs) were 
obtained as described [49] and used at early passage (P2-
P5). The human breast adenocarcinoma-derived MCF7 
cell line was obtained from the European Collection of 
Cell Cultures (ECACC). Breast cancer-derived MDA-
MB-231 cells infected with a triple-fusion protein reporter 
construct encoding herpes simplex virus thymidine kinase 
1, green fluorescent protein (GFP) and firefly luciferase 
(TGL) for bioluminescent tracking (MDA-MB-231-TGL 
cells) were kindly provided by Dr. J. Massagué [36]. 
For proliferation assays, primary MEFs were plated 
in triplicates at 2x104 cells on 35 mm dishes. Every 48 
h, starting 24 h after plating (time 0), cells were fixed 
in 4% formaldehyde (FA), and stained with 1% crystal 
violet for 30 min. After solubilization in 15% acetic acid, 
absorbance was measured at 570 nm.
For high density culture assays, primary MEFs were 
plated at 4x104 cells on 35 mm dishes and the culture 
medium was changed every 48 h. 15 days after plating, 
cells were fixed, stained and cell density was measured as 
described above.
For cell cycle analysis, primary MEFs were plated 
at 7x105 cells on 100 mm dishes and maintained in 
DMEM with 10% FBS for 48 h (Asynchronous), without 
FBS for further 48 h (No serum) or FBS was added for 
16 h after 48 h serum starvation (Re-stimulated). Cells 
were collected, fixed, stained with propidium iodide and 
analyzed by flow cytometry as previously described [42, 
50].
In vitro transformation assays
For immortalization assays (3T3 protocol), 1.75x105 
MEFs of each genotype were plated on 35 mm dishes. 
Every three days cells were trypsinized, counted and 
replated at the same density. The number of divisions 
(population doubling level, PDL) was calculated using the 
following formula: PDL = 3.32 x (logNf-logNi), where 
Ni is the initial number of cells and Nf the number of 
cells collected for each point [51]. Cells were considered 
senescent when no significant increase in cell number was 
observed for three consecutive passages and immortalized 
when cell number increased for three consecutive passages 
after senescence. 
For oncogene transformation assays, RhoE+/+ and 
RhoEgt/gt MEFs were infected with empty pLPC vector 
(control), pLPC-RasV12 or pLPC-E1A/RasV12 and seeded 
at a density of 2x103 cells on 100 mm dishes per triplicate. 
Cells were grown in DMEM with 10% FBS for 1-3 weeks 
and then they were fixed with formaldehyde 4% and 
stained with crystal violet for colony visualization.
In vivo tumorigenesis assays
RhoE+/+ and RhoEgt/gt MEFs previously infected 
with pLPC-E1A/RasV12 were subcutaneously injected into 
both posterior flanks of 16 nude mice, respectively (4x105 
cells in 100 µl of PBS per injection). Tumor volume was 
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measured with a caliper and calculated every four days 
by using the following formula: V=AxB2/2 (cm3), where 
A is the major diameter and B the perpendicular tumor 
diameter. After 5 weeks, mice were sacrificed and tumors 
were removed and processed for histological analysis.
For the chemical induction of papillomas in vivo, we 
used the DMBA-TPA two-step carcinogenesis protocol, in 
which DMBA causes a mutation in Ha-Ras as the initiating 
event and the tumor promoter TPA activates PKC [34, 35]. 
A single dose of DMBA (32 µg in 0.2 ml acetone) followed 
by weekly doses of TPA (12.5 µg in 0.2 ml acetone) for 
15 weeks were applied to the shaved back of 14 RhoE+/+ 
and 14 RhoE+/gt mice. Lesions were counted weekly for 40 
weeks. At the end of the experiment, mice were sacrificed 
and tumors were processed for histopathology analysis and 
classified as epithelial hyperplasia, papilloma or squamous 
cell carcinoma.
Western blotting and immunohistochemistry
Cell samples were processed for Western blotting 
and for subcellular fractionation as previously described 
[8, 42, 52].
The following antibodies were used for Western 
blotting: anti-RhoE (Merck Millipore, Darmstadt, 
Germany); anti-p27Kip1 and anti-p21Cip1 (Santa Cruz 
Biotechnology, Santa Cruz, CA, USA); anti-Actin and 
anti-β-tubulin (Sigma-Aldrich, St. Louis, MO, USA); anti-
lamin A (Cell Signaling, Beverly, MA, USA). Blots were 
developed using enhanced chemiluminescence (ECL Plus, 
GE Healthcare Life Sciences, Fairfield, CT, USA).
For immunohistochemistry, PCNA antibodies (Santa 
Cruz Biotechnology) were used on paraffin embedded skin 
sections.
RhoE silencing
Control lentivirus (pLKO.1) or three different RhoE 
shRNA constructs from Mission Library (Sigma-Aldrich) 
were used to knock-down RhoE expression. The shRNA 
sequences were:
shRhoE #3 (TRCN330303):CCGGATCCTAATCA
GAACGTGAAATCTCGAGATTTCACGTTCTGATTA
GGATTTTTTG
shRhoE #4 (TRCN330304):CCGGCGGACAGAT
GTTAGTACATTACTCGAGTAATGTACTAACATCTG
TC CGTTTTTG
shRhoE #5 (TRCN330305):CCGGGAGAGCCAC
AAAGCGGATTTCCTCGAGGAAATCCGCTTTGTGG
CTCTCTTTTTG
We used shRhoE #3, shRhoE #4 and shRhoE #5 to 
transduce MDA-MB-231-TGL cells and shRhoE #3 to 
transduce MCF7 cells. After infection, cells were selected 
with 2.5 µg/ml Puromycin.
Experimental metastasis assay and 
bioluminescence imaging
Control and two RhoE knocked-down (shRhoE 
#3 and shRhoE #5) MDA-MB-231-TGL cells from 
subconfluent cultures were injected (1x106 in 0.1 
ml PBS) into the tail vein of nude mice. For in vivo 
bioluminescence imaging, mice were anesthetized and 
injected intraperitoneally with 3 mg of d-luciferin (15 mg/
ml in PBS). Imaging was completed between 5 and 30 min 
after injection with a Xenogen IVIS (IVISR Lumina II) 
system coupled to Living Image acquisition and analysis 
software (Xenogen Corporation). For bioluminescence 
intensity (BLI) plots, photon flux was calculated as 
described [36]. Measurements were performed once a 
week starting 1 week after tail vein injection and up to 9 
weeks.
Statistical analysis
Data were analyzed by the Student’s t test, ANOVA 
or the Mantel-Cox test using the GraphPad Prism software. 
Differences were considered significant if p < 0.05.
ACKNOWLEDGMENTS
We thank Dr. J. Massague for the MDA-MB-231-
TGL cells.
GRANT SUPPORT
This work was supported by grants from the 
Instituto de Salud Carlos III (to IPR and RMG), MINECO 
SAF2013-49176-C2-1-R and SAF2012-32117 (to IPR and 
IP, respectively) and Universidad CEU Cardenal Herrera 
Santander-Copernicus (to IPR). The work was also 
supported by fellowships from the Generalitat Valenciana 
(to MHS).
CONFLICTS OF INTEREST
There is no conflict of interest.
REFERENCES
1. Guasch RM, Scambler P, Jones GE and Ridley AJ. RhoE 
regulates actin cytoskeleton organization and cell migration. 
Mol Cell Biol. 1998; 18:4761-4771.
2. Komander D, Garg R, Wan PT, Ridley AJ and Barford D. 
Mechanism of multi-site phosphorylation from a ROCK-
I:RhoE complex structure. The EMBO journal. 2008; 
27:3175-3185.
3. Riento K, Guasch RM, Garg R, Jin B and Ridley AJ. RhoE 
binds to ROCK I and inhibits downstream signaling. Mol 
Oncotarget17489www.impactjournals.com/oncotarget
Cell Biol. 2003; 23:4219-4229.
4. Foster R, Hu KQ, Lu Y, Nolan KM, Thissen J and 
Settleman J. Identification of a novel human Rho protein 
with unusual properties: GTPase deficiency and in vivo 
farnesylation. Mol Cell Biol. 1996; 16:2689-2699.
5. Chardin P. Function and regulation of Rnd proteins. Nat 
Rev Mol Cell Biol. 2006; 7:54-62.
6. Villalonga P, Guasch RM, Riento K and Ridley AJ. 
RhoE inhibits cell cycle progression and Ras-induced 
transformation. Mol Cell Biol. 2004; 24:7829-7840.
7. Bektic J, Pfeil K, Berger AP, Ramoner R, Pelzer A, Schafer 
G, Kofler K, Bartsch G and Klocker H. Small G-protein 
RhoE is underexpressed in prostate cancer and induces cell 
cycle arrest and apoptosis. The Prostate. 2005; 64:332-340.
8. Poch E, Minambres R, Mocholi E, Ivorra C, Perez-Arago A, 
Guerri C, Perez-Roger I and Guasch RM. RhoE interferes 
with Rb inactivation and regulates the proliferation and 
survival of the U87 human glioblastoma cell line. Exp Cell 
Res. 2007; 313:719-731.
9. Lonjedo M, Poch E, Mocholi E, Hernandez-Sanchez 
M, Ivorra C, Franke TF, Guasch RM and Perez-Roger I. 
The Rho family member RhoE interacts with Skp2 and is 
degraded at the proteasome during cell cycle progression. 
The Journal of biological chemistry. 2013; 288:30872-
30882.
10. Boswell SA, Ongusaha PP, Nghiem P and Lee SW. The 
protective role of a small GTPase RhoE against UVB-
induced DNA damage in keratinocytes. The Journal of 
biological chemistry. 2007; 282:4850-4858.
11. Ongusaha PP, Kim HG, Boswell SA, Ridley AJ, Der CJ, 
Dotto GP, Kim YB, Aaronson SA and Lee SW. RhoE is a 
pro-survival p53 target gene that inhibits ROCK I-mediated 
apoptosis in response to genotoxic stress. Current biology : 
CB. 2006; 16:2466-2472.
12. Belgiovine C, Frapolli R, Bonezzi K, Chiodi I, Favero 
F, Mello-Grand M, Dei Tos AP, Giulotto E, Taraboletti 
G, D’Incalci M and Mondello C. Reduced expression of 
the ROCK inhibitor Rnd3 is associated with increased 
invasiveness and metastatic potential in mesenchymal 
tumor cells. PloS one. 2010; 5:e14154.
13. Grise F, Sena S, Bidaud-Meynard A, Baud J, Hiriart JB, 
Makki K, Dugot-Senant N, Staedel C, Bioulac-Sage P, 
Zucman-Rossi J, Rosenbaum J and Moreau V. Rnd3/RhoE 
Is down-regulated in hepatocellular carcinoma and controls 
cellular invasion. Hepatology. 2012; 55:1766-1775.
14. Luo H, Dong Z, Zou J, Zeng Q, Wu D and Liu L. Down-
regulation of RhoE is associated with progression and poor 
prognosis in hepatocellular carcinoma. J Surg Oncol. 2012; 
105:699-704.
15. Zhu Z, Todorova K, Lee KK, Wang J, Kwon E, Kehayov I, 
Kim HG, Kolev V, Dotto GP, Lee SW and Mandinova A. 
Small GTPase RhoE/Rnd3 Is a Critical Regulator of Notch1 
Signaling. Cancer Res. 2014; 74:2082-2093.
16. Chen J, Zhou H, Li Q, Qiu M, Li Z, Tang Q, Liu M, Zhu 
Y, Huang J, Lang N, Liu Z, Deng Y, Zhang S and Bi F. 
Epigenetic modification of RhoE expression in gastric 
cancer cells. Oncol Rep. 2011; 25:173-180.
17. Fu Y, Liu X, Zhou N, Du L, Sun Y, Zhang X and Ge Y. 
MicroRNA-200b stimulates tumour growth in TGFBR2-
null colorectal cancers by negatively regulating p27/kip1. 
J Cell Physiol. 2014; 229:772-782.
18. Hidalgo-Carcedo C, Hooper S, Chaudhry SI, Williamson 
P, Harrington K, Leitinger B and Sahai E. Collective cell 
migration requires suppression of actomyosin at cell-cell 
contacts mediated by DDR1 and the cell polarity regulators 
Par3 and Par6. Nature cell biology. 2011; 13:49-58.
19. Pinner S and Sahai E. PDK1 regulates cancer cell motility 
by antagonising inhibition of ROCK1 by RhoE. Nature cell 
biology. 2008; 10:127-137.
20. Cuiyan Z, Jie H, Fang Z, Kezhi Z, Junting W, Susheng 
S, Xiaoli F, Ning L, Xinhua M, Zhaoli C, Kang S, Bin 
Q, Baozhong L, Sheng C and Meihua X. Overexpression 
of RhoE in Non-small Cell Lung Cancer (NSCLC) is 
associated with smoking and correlates with DNA copy 
number changes. Cancer biology & therapy. 2007; 6:335-
342.
21. Zhang C, Zhou F, Li N, Shi S, Feng X, Chen Z, Hang J, Qiu 
B, Li B, Chang S, Wan J, Shao K, Xing X, Tan X, Wang Z, 
Xiong M, et al. Overexpression of RhoE has a prognostic 
value in non-small cell lung cancer. Ann Surg Oncol. 2007; 
14:2628-2635.
22. Feng B, Li K, Zhong H, Ren G, Wang H, Shang Y, Bai M, 
Liang J, Wang X and Fan D. RhoE promotes metastasis in 
gastric cancer through a mechanism dependent on enhanced 
expression of CXCR4. PloS one. 2013; 8:e81709.
23. Trojan L, Schaaf A, Steidler A, Haak M, Thalmann G, 
Knoll T, Gretz N, Alken P and Michel MS. Identification 
of metastasis-associated genes in prostate cancer by genetic 
profiling of human prostate cancer cell lines. Anticancer 
research. 2005; 25:183-191.
24. Zhou J, Li K, Gu Y, Feng B, Ren G, Zhang L, Wang 
Y, Nie Y and Fan D. Transcriptional up-regulation of 
RhoE by hypoxia-inducible factor (HIF)-1 promotes 
epithelial to mesenchymal transition of gastric cancer cells 
during hypoxia. Biochemical and biophysical research 
communications. 2011; 415:348-354.
25. Zhou J, Yang J, Li K, Mo P, Feng B, Wang X, Nie Y and 
Fan D. RhoE is associated with relapse and prognosis of 
patients with colorectal cancer. Ann Surg Oncol. 2013; 
20:175-182.
26. Klein RM and Aplin AE. Rnd3 regulation of the actin 
cytoskeleton promotes melanoma migration and invasive 
outgrowth in three dimensions. Cancer Res. 2009; 69:2224-
2233.
27. Mocholi E, Ballester-Lurbe B, Arque G, Poch E, Peris B, 
Guerri C, Dierssen M, Guasch RM, Terrado J and Perez-
Roger I. RhoE deficiency produces postnatal lethality, 
profound motor deficits and neurodevelopmental delay in 
Oncotarget17490www.impactjournals.com/oncotarget
mice. PloS one. 2011; 6:e19236.
28. St Croix B, Sheehan C, Rak JW, Florenes VA, Slingerland 
JM and Kerbel RS. E-Cadherin-dependent growth 
suppression is mediated by the cyclin-dependent kinase 
inhibitor p27(KIP1). The Journal of cell biology. 1998; 
142:557-571.
29. Levenberg S, Yarden A, Kam Z and Geiger B. p27 is 
involved in N-cadherin-mediated contact inhibition of cell 
growth and S-phase entry. Oncogene. 1999; 18:869-876.
30. Motti ML, Califano D, Baldassarre G, Celetti A, Merolla 
F, Forzati F, Napolitano M, Tavernise B, Fusco A and 
Viglietto G. Reduced E-cadherin expression contributes 
to the loss of p27kip1-mediated mechanism of contact 
inhibition in thyroid anaplastic carcinomas. Carcinogenesis. 
2005; 26:1021-1034.
31. Blagosklonny MV. Are p27 and p21 cytoplasmic 
oncoproteins? Cell cycle. 2002; 1:391-393.
32. Serres MP, Zlotek-Zlotkiewicz E, Concha C, Gurian-West 
M, Daburon V, Roberts JM and Besson A. Cytoplasmic p27 
is oncogenic and cooperates with Ras both in vivo and in 
vitro. Oncogene. 2011; 30:2846-2858.
33. Todaro GJ and Green H. Quantitative studies of the growth 
of mouse embryo cells in culture and their development into 
established lines. The Journal of cell biology. 1963; 17:299-
313.
34. Kemp CJ. Multistep skin cancer in mice as a model to study 
the evolution of cancer cells. Seminars in cancer biology. 
2005; 15:460-473.
35. Quintanilla M, Brown K, Ramsden M and Balmain A. 
Carcinogen-specific mutation and amplification of Ha-ras 
during mouse skin carcinogenesis. Nature. 1986; 322:78-80.
36. Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, 
Viale A, Olshen AB, Gerald WL and Massague J. Genes 
that mediate breast cancer metastasis to lung. Nature. 2005; 
436:518-524.
37. Nguyen DX, Bos PD and Massague J. Metastasis: from 
dissemination to organ-specific colonization. Nat Rev 
Cancer. 2009; 9:274-284.
38. Chu IM, Hengst L and Slingerland JM. The Cdk inhibitor 
p27 in human cancer: prognostic potential and relevance to 
anticancer therapy. Nat Rev Cancer. 2008; 8:253-267.
39. Hanahan D and Weinberg RA. Hallmarks of cancer: the 
next generation. Cell. 2011; 144:646-674.
40. Leontieva OV, Demidenko ZN and Blagosklonny MV. 
Contact inhibition and high cell density deactivate the 
mammalian target of rapamycin pathway, thus suppressing 
the senescence program. Proceedings of the National 
Academy of Sciences of the United States of America. 
2014; 111:8832-8837.
41. Lu Z and Hunter T. Ubiquitylation and proteasomal 
degradation of the p21(Cip1), p27(Kip1) and p57(Kip2) 
CDK inhibitors. Cell cycle. 2010; 9:2342-2352.
42. Andreu EJ, Lledo E, Poch E, Ivorra C, Albero MP, 
Martinez-Climent JA, Montiel-Duarte C, Rifon J, Perez-
Calvo J, Arbona C, Prosper F and Perez-Roger I. BCR-
ABL induces the expression of Skp2 through the PI3K 
pathway to promote p27Kip1 degradation and proliferation 
of chronic myelogenous leukemia cells. Cancer Res. 2005; 
65:3264-3272.
43. Borriello A, Cucciolla V, Oliva A, Zappia V and Della 
Ragione F. p27Kip1 metabolism: a fascinating labyrinth. 
Cell cycle. 2007; 6:1053-1061.
44. Liebig T, Erasmus J, Kalaji R, Davies D, Loirand G, 
Ridley A and Braga VM. RhoE Is required for keratinocyte 
differentiation and stratification. Molecular biology of the 
cell. 2009; 20:452-463.
45. Madigan JP, Bodemann BO, Brady DC, Dewar BJ, Keller 
PJ, Leitges M, Philips MR, Ridley AJ, Der CJ and Cox AD. 
Regulation of Rnd3 localization and function by protein 
kinase C alpha-mediated phosphorylation. Biochem J. 2009; 
424:153-161.
46. Riento K, Totty N, Villalonga P, Garg R, Guasch R and 
Ridley AJ. RhoE function is regulated by ROCK I-mediated 
phosphorylation. The EMBO journal. 2005; 24:1170-1180.
47. Pinner S and Sahai E. Imaging amoeboid cancer cell 
motility in vivo. J Microsc. 2008; 231:441-445.
48. Zambrowicz BP, Friedrich GA, Buxton EC, Lilleberg 
SL, Person C and Sands AT. Disruption and sequence 
identification of 2,000 genes in mouse embryonic stem 
cells. Nature. 1998; 392:608-611.
49. Perez-Roger I, Kim SH, Griffiths B, Sewing A and Land 
H. Cyclins D1 and D2 mediate myc-induced proliferation 
via sequestration of p27(Kip1) and p21(Cip1). The EMBO 
journal. 1999; 18:5310-5320.
50. Albero MP, Vaquer JM, Andreu EJ, Villanueva JJ, Franch 
L, Ivorra C, Poch E, Agirre X, Prosper F and Perez-Roger 
I. Bortezomib decreases Rb phosphorylation and induces 
caspase-dependent apoptosis in Imatinib-sensitive and 
-resistant Bcr-Abl1-expressing cells. Oncogene. 2010; 
29:3276-3286.
51. Hayflick L. (1973). Tissue culture: methods and 
applications. (New York,: Academic Press).
52. Ishida N, Hara T, Kamura T, Yoshida M, Nakayama K and 
Nakayama KI. Phosphorylation of p27Kip1 on serine 10 is 
required for its binding to CRM1 and nuclear export. The 
Journal of biological chemistry. 2002; 277:14355-14358.
